Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Survival of patients with prostate cancer in Yazd, Iran.

Zahir ST, Nazemian MR, Zand S, Zare S.

Asian Pac J Cancer Prev. 2014;15(2):883-6.

2.

Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.

Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4.

3.

Survival of patients with lung cancer, Yazd, Iran.

Zahir ST, Mirtalebi M.

Asian Pac J Cancer Prev. 2012;13(9):4387-91.

4.

Incidence and trends of malignant and benign pancreatic lesions in Yazd, Iran between 2001 and 2011.

Zahir ST, Arjmand A, Kargar S, Neishaboury M.

Asian Pac J Cancer Prev. 2013;14(4):2631-5.

5.

Prostate Cancer in Iran: Trends in Incidence and Morphological and Epidemiological Characteristics.

Pakzad R, Rafiemanesh H, Ghoncheh M, Sarmad A, Salehiniya H, Hosseini S, Sepehri Z, Afshari-Moghadam A.

Asian Pac J Cancer Prev. 2016;17(2):839-43.

6.

Impact of surgical margin status on prostate-cancer-specific mortality.

Chalfin HJ, Dinizo M, Trock BJ, Feng Z, Partin AW, Walsh PC, Humphreys E, Han M.

BJU Int. 2012 Dec;110(11):1684-9. doi: 10.1111/j.1464-410X.2012.11371.x. Epub 2012 Jul 12.

7.

Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.

Jonsson E, Sigbjarnarson HP, Tomasson J, Benediktsdottir KR, Tryggvadottir L, Hrafnkelsson J, Olafsdottir EJ, Tulinius H, Jonasson JG.

Scand J Urol Nephrol. 2006;40(4):265-71.

PMID:
16916765
8.

Survey of clinical and pathological characteristics and outcomes of patients with prostate cancer.

Alizadeh M, Alizadeh S.

Glob J Health Sci. 2014 Sep 18;6(7 Spec No):49-57. doi: 10.5539/gjhs.v6n7p49.

9.

Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS, Yao SL.

Eur Urol. 2015 Nov;68(5):805-11. doi: 10.1016/j.eururo.2015.03.021. Epub 2015 Mar 21.

10.

The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona.

Murta-Nascimento C, Romero AI, Sala M, Lorente JA, Bellmunt J, Rodero NJ, Lloreta J, Hospital À, Burón A, Castells X, Macià F.

Eur J Cancer Prev. 2015 Jul;24(4):335-9. doi: 10.1097/CEJ.0000000000000075.

PMID:
25075878
11.

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM.

BJU Int. 2012 Oct;110(8):1122-8. doi: 10.1111/j.1464-410X.2012.10986.x. Epub 2012 Feb 28.

12.

Changing trends in symptomatology, diagnostics, stage and survival of prostate cancer in Northern Finland during a period of 20 years.

Kavasmaa OT, Tyomkin DB, Mehik A, Parpala TM, Tonttila P, Paananen I, Kunelius P, Vaarala MH, Ohtonen P, Hellström PA.

World J Surg Oncol. 2013 Oct 5;11:258. doi: 10.1186/1477-7819-11-258.

13.

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MK, Ritchie AW, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR.

Eur Urol. 2015 Jun;67(6):1028-38. doi: 10.1016/j.eururo.2014.09.032. Epub 2014 Oct 6.

14.

Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.

Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.

J Urol. 2005 Dec;174(6):2181-5.

PMID:
16280760
15.

Endometrial adenocarcinoma: clinicopathologic and survival characteristics in Yazd, Iran.

Binesh F, Akhavan A, Behniafard N, Jalilian S.

Asian Pac J Cancer Prev. 2014;15(6):2797-801.

16.

Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.

Ang M, Rajcic B, Foreman D, Moretti K, O'Callaghan ME.

BJU Int. 2016 Apr;117 Suppl 4:68-75. doi: 10.1111/bju.13411. Epub 2016 Feb 18.

17.

Prognostic Gleason grade grouping: data based on the modified Gleason scoring system.

Pierorazio PM, Walsh PC, Partin AW, Epstein JI.

BJU Int. 2013 May;111(5):753-60. doi: 10.1111/j.1464-410X.2012.11611.x. Epub 2013 Mar 6.

18.

Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.

Miyamoto S, Ito K, Miyakubo M, Suzuki R, Yamamoto T, Suzuki K, Suzuki K, Yamanaka H.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):75-86. doi: 10.1038/pcan.2011.47. Epub 2011 Oct 11.

PMID:
21986985
19.

The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort.

Gomez-Iturriaga A, Cabeza Á, Pastor J, Jove J, Casaña M, Caamaño AG, Mengual J, Henríquez I, Muñoz J, Hervás A, Segundo CG.

Clin Transl Oncol. 2016 Oct;18(10):1026-33. doi: 10.1007/s12094-016-1481-5. Epub 2016 Jan 19.

PMID:
26781470
20.

Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.

Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, Kakoi N, Kawamura S, Tochigi T, Habuchi T, Ohyama C, Arai Y.

BJU Int. 2013 May;111(6):914-20. doi: 10.1111/j.1464-410X.2012.11658.x. Epub 2013 Jan 15.

Supplemental Content

Support Center